Discover
VOR
Vor Biopharma Inc.
14.10
2 x 10.46
1 x 17.76
bid
ask
+
0.29
2.10%
11:01 AM
timesize
| Ytd | 7.80% | |
| 1y | -2.08% |
13.82
day range
14.59
2.62
52 week range
65.80
| Open | 13.82 | Prev Close | 13.81 | Low | 13.82 | High | 14.59 | Mkt Cap | 690.22M |
| Vol | 236.65K | Avg Vol | 1.00M | EPS | -70.50 | P/E | N/A | Forward P/E | -0.74 |
| Beta | -0.41 | Short Ratio | 2.99 | Inst. Own | 81.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 14.79 | 200-d Avg | 23.23 | 1yr Est | 13.21 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-06 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | -1.61 | -282.46% |
| 2025-05-14 | 2025-03 | 0 | N/A | -0.01 | -4.00% |
| 2025-05-14 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-03-20 | 2024-12 | 0 | N/A | -0.19 | -76.00% |
| 2025-03-20 | 2024-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-10 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-11-08 | Baird | Upgrade | Outperform | Outperform |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-06 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-09-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-28 | ANG ROBERT M.D. | Chief Executive Officer | 830.93K | Stock Award(Grant) |
| 2024-06-02 | ATTAR EYAL C | Officer | 96.06K | Sale |
| 2024-01-28 | CHAKRABORTY TIRTHA | Officer | 187.70K | Stock Award(Grant) |
| 2024-01-28 | JORGENSEN NATHAN D. | Chief Financial Officer | 198.45K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 22.75M | 19.75M | 33.13% |
| 2024-09-29 | FMR, LLC | 7.07M | 6.14M | 10.30% |
| 2024-09-29 | 5AM Venture Management, LLC | 6.36M | 5.52M | 9.26% |
| 2024-09-29 | Hudson Bay Capital Management Lp | 2.47M | 2.14M | 3.59% |
| 2024-09-29 | Vanguard Group Inc | 1.95M | 1.70M | 2.85% |
| 2024-09-29 | Cowen and Company, LLC | 1.22M | 1.06M | 1.78% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Growth Company Fund | 1.44M | 1.25M | 2.09% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.39M | 1.20M | 2.02% |
| 2024-10-30 | Variable Insurance Products Fund-Growth Portfolio | 618.40K | 536.83K | 0.90% |
| 2024-10-30 | Fidelity Capital Appreciation Fund | 610.41K | 529.89K | 0.89% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 519.63K | 451.09K | 0.76% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 501.60K | 435.44K | 0.73% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2025-09-19 |
